一分钟看懂
这是一项关于多发性骨髓瘤的I 期 / II 期研究，登记的药物或干预包括CT0596，当前状态为招募中。登记地点显示中国苏州、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
CT0596 · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Soochow University · 苏州
- Renji Hospital,Shanghai Jiao Tong University School Of Medicine · 上海
公开的入选条件
- * Voluntarily participate in the trial; fully understand and sign the informed consent form (ICF); willing and able to comply with all trial procedures.
- * Age ≥ 18 years, male or female.
- * Patients with relapsed/refractory multiple myeloma (R/R MM) who have received at least 3 prior lines of therapy, including at least one proteasome inhibitor (PI), at least one immunomodulatory agent (IMiD), and at least one anti-CD38 monoclonal antibody.
- * Relapsed/refractory disease defined per IMWG 2016 response criteria,.
- * Must have measurable disease:
- * Life expectancy ≥ 12 weeks.
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- * Must have Adequate organ function
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07760454；登记信息更新于 2026-09-17。